March 2026 Research Update

This month added more human evidence that blocking IL-6 with siltuximab can be followed by disease control in idiopathic multicentric Castleman disease (iMCD), while also showing that some situations need additional approaches beyond IL-6 blockade. In a small real-world group, many people had responses and the side effects reported were limited. Separate case-based reports highlighted that very severe inflammatory presentations may need temporary "bridge" support while diagnosis and longer-term treatment are put in place, and that iMCD can sometimes overlap with other serious conditions that change what treatments are tried. [1] [2] [3]

In routine care across 14 adults receiving first-line siltuximab (an anti-IL-6 antibody), most had tumor and symptom responses by the study's response criteria, and many were still alive at the time the data were summarized. Reported side effects included a small number of grade 2 or higher problems such as high blood pressure, liver enzyme changes, and pneumonia, and there were no infusion reactions reported in this group. For patients, this strengthens the picture of siltuximab as a commonly used IL-6-targeted option with responses observed outside of clinical trials, while still leaving open how well these results carry over to different patient groups because the study was small and retrospective. [1]

A case of fulminant iMCD-TAFRO described a period where the illness looked like a blood vessel injury problem similar to TTP, and the team used short-term measures (plasma exchange with fresh frozen plasma, steroids, and anisodamine) while the diagnosis was being confirmed, followed by siltuximab. The report described improvement in blood counts and a remission reported at 1 year, with a later relapse involving pulmonary hypertension managed with intensified immune suppression; transient anticholinergic side effects from anisodamine were also described. For patients, this illustrates that in the most rapidly progressive presentations, care can involve staged treatments and close monitoring of organ problems, but it remains uncertain which parts of the multi-step approach were most responsible for recovery because it was a single patient. [2]

Another case report described iMCD that later transformed into a T-cell lymphoma complicated by hemophagocytic lymphohistiocytosis (HLH), with EBV detected in the blood throughout the course. The patient improved quickly after ruxolitinib with dexamethasone and then ruxolitinib plus CHOP, but later died after an acute stroke with bleeding in the brain. For patients, this underscores that a small subset of people may develop overlapping or evolving conditions that lead teams to try different immune-targeting and chemotherapy combinations, but this report cannot show how often this happens or how well the approach works across patients. [3]

Taken together, these studies mostly add near-term understanding rather than changing what any one person should do: they show that IL-6 targeting with siltuximab continues to have supportive real-world evidence in iMCD, and that severe or complicated situations sometimes involve additional, temporary treatments or entirely different treatment paths. The most directly patient-relevant evidence here is the small retrospective siltuximab experience, while the case reports mainly illustrate what can happen in unusual, high-severity scenarios. What remains uncertain is how to predict who will follow a straightforward course on IL-6 blockade versus who may need additional approaches, because the new information came from a small cohort and individual cases. [1] [2] [3]

This month clarified that predicting the course of Castleman-related illnesses remains difficult, and that timing of recovery can vary by organ system. A Western cohort study found that an existing iMCD risk score (iMCD-IPI) did not clearly separate people into groups with very different survival in that setting. Other studies highlighted specific situations where outcomes can differ, including slower recovery of some TAFRO features, kidney involvement in children that often improved with Castleman-directed and immune-suppressing treatments, and poorer survival in one subgroup of KSHV-related lymphoma based on viral subtype. [4] [5] [6] [7]

In 51 people with iMCD at Mayo Clinic, iMCD-IPI risk groups showed limited separation for overall survival, and the observed survival by group looked different from the original population used to build the score. This matters to patients because it suggests that a single published risk index may not perform the same way in every country or care setting, and predictions about the future can be less certain when applied to a new group. The study helps clarify that outcome tools may need further testing and possibly adjustment across different populations. [4]

A small series of 7 people with TAFRO syndrome reported that some problems tended to improve earlier than others, with kidney function recovering sooner than low platelets and fluid overload. The median time to recovery was 7 days for kidney dysfunction and 46 days for thrombocytopenia, showing a wide spread across domains. For patients and caregivers, this provides a more concrete expectation that "getting better" may happen in stages, although the report does not indicate how different treatments influenced these timelines. [5]

In a pediatric hospital cohort of 42 children with Castleman disease, nearly half had kidney-related findings such as protein in the urine, inflammation in the kidneys, nephrotic syndrome, or acute kidney failure. These kidney issues often appeared around the start of Castleman disease and were reported to improve after Castleman-directed treatment and immune-suppressing medicines; one biopsy showed minimal change disease. For families, this emphasizes that kidney involvement can be part of the illness picture in children and may improve alongside treatment of the underlying Castleman disease, while also showing that kidney problems can sometimes appear even during remission. [6]

In 143 people with HIV and KSHV-associated diseases (which can include Castleman-related conditions), the KSHV K1 viral subtype generally did not match a specific disease presentation and usually did not change survival. One exception was primary effusion lymphoma, where subtype A was linked to worse survival than other subtypes in that subgroup. For patients, this is mainly research that helps clarify that viral genetics may matter for certain KSHV-driven cancers, but it is not presented as a factor that currently guides day-to-day Castleman disease care in the summaries provided. [7]

These studies add context for what to expect over time and how uncertain prognosis tools can be when applied to new patient groups. The iMCD-IPI validation suggests that a score developed in one setting may not predict survival well in another, which helps explain why prognosis conversations can vary and why more data are still needed. The TAFRO recovery timelines and the pediatric kidney series provide practical, near-term understanding that different organ problems may improve at different speeds and that kidney involvement is not rare in children, even though the reports do not identify a single best way to monitor or treat these issues. The viral subtype study is most relevant to people dealing with KSHV-related conditions and is best viewed as longer-term background research rather than something that changes care right now. [4] [5] [6] [7]

This month included several reports that sharpen the "how it is recognized" side of Castleman disease and remind readers that real-world cases can look very different from one another. One paper proposed a more standardized way to grade lymph node changes in iMCD so that pathology findings can be compared more consistently. Case reports also showed uncommon settings for unicentric Castleman disease (including around breast implants and in the mediastinum) and highlighted rare but serious overlaps between Castleman disease and HHV-8 related conditions like Kaposi sarcoma. [8] [9] [10] [11] [12] [13]

A case-based paper introduced a quantitative grading system for key microscope features seen in iMCD lymph nodes, and showed how two patients (one iMCD-NOS and one iMCD-TAFRO) had different grading patterns. The authors argued that combining this kind of graded pathology with imaging and lab findings can support diagnosis and subtype differentiation. For patients, the value is mainly in making diagnoses more consistent between centers and helping research compare people more fairly, but this approach still needs broader testing beyond two cases. [8]

Two case reports focused on localized (unicentric) disease in unusual locations and described successful short-term outcomes after surgery. One person with a mediastinal mass had preoperative embolization followed by robotic-assisted removal with low blood loss and no recurrence seen on imaging at 3 to 6 months. Another person with a breast mass and long-standing implants was found to have hyaline-vascular unicentric Castleman disease on surgical pathology; PET-CT two months after surgery showed no residual disease, and no signs of malignancy were reported more than six months after resection. [10] [9]

Several reports highlighted overlap between Castleman-like lymph node findings and viral or autoimmune conditions, which can complicate diagnosis and expectations. Two women with systemic lupus erythematosus had lymph node biopsies read as plasmacytic Castleman disease and improved clinically after rituximab, but long-term follow-up was not available. Separately, a single HIV-negative man with HHV-8 associated multicentric Castleman disease developed an unusual angiomatous subtype of penile Kaposi sarcoma that was HHV-8 positive on tissue testing, and he later died from multiorgan failure despite treatment. [12] [11]

A CDC investigation described suspected donor-derived KSHV transmission in U.S. solid organ transplant recipients, where nearly half developed post-transplant KSHV infection and some developed Kaposi sarcoma, multicentric Castleman disease, or related inflammatory syndromes. The report also noted donor risk factors such as nonmedical drug use and emphasized the role of testing and reporting, while acknowledging uncertainty about whether some cases could reflect recipient reactivation rather than donor transmission. For patients, this provides background on how KSHV-related diseases, including multicentric Castleman disease, can appear after transplantation in certain circumstances, but the report is descriptive and does not evaluate a specific prevention or treatment strategy. [13]

These studies mainly add understanding about how Castleman disease is identified and the range of situations where it can appear, rather than pointing to a single new treatment. The proposed pathology grading system may matter later if it becomes widely used, because it could make diagnoses and subtypes more consistent across hospitals. The unicentric case reports reinforce that complete surgical removal can be followed by no recurrence on short follow-up in individual patients, but they cannot predict outcomes for everyone. The autoimmune, HHV-8, and transplant-related reports help clarify that Castleman disease can overlap with other immune and viral conditions, and that in some contexts the course can be severe, but the frequency of these events and the best way to anticipate them remain uncertain from case reports and surveillance data alone. [8] [9] [10] [12] [11] [13]